{
  "id": 12745603,
  "title": "Glaukos CDO Tomas Navratil sells $251,120 in company stock",
  "url": "https://urgent.news/2026/10/07/glaukos-cdo-tomas-navratil-sells-251-120-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-07T23:46:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/glaukos-cdo-tomas-navratil-sells-251120-in-company-stock-93CH-4937725"
  },
  "original_language": "en",
  "account": "Glaukos Corp (NASDAQ:GKOS) Chief Development Officer Tomas Navratil executed three separate sales of company stock on October 5, 2026, totalling 1,527 shares valued at $251,120. The trades occurred at prices fluctuating between $163.93 and $165.60 per share, as per a Rule 10b5-1 trading plan initiated on June 12, 2026. The shares were divided into three sales: 888 shares at $163.93, 327 shares at $164.78, and 312 shares at $165.60. This comes as Glaukos shares have soared 104% in the past year, presently trading at $172.18. Despite this, InvestingPro's analysis suggests the stock is currently overvalued. Mr. Navratil's ownership now stands at 69,291 shares, including 38,817 restricted stock units yet to vest. Glaukos, valued at $9.53 billion, has seen robust revenue growth of 41.6% but remains unprofitable with an EPS of -$3.25. The company reported a stellar Q2 2026 earning of $185.6 million, surpassing the anticipated $151.5 million. Following the results, several firms revised their price targets: H.C. Wainwright to $195, Needham to $201, Stifel to $190, and Truist Securities to $215. Stifel maintained a Buy rating, predicting a potential $1.0 billion revenue for 2027, underpinned by the performance of its Epioxa, iDose, and Glaucoma products.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}